Background
Bronchiectasis is a progressive disease characterised by permanent dilatation of bronchi, impairment of mucociliary clearance, and retention of secretions. Recurrent respiratory infections are a key feature of bronchiectasis, with the majority of research focusing on the role of bacteria in stable patients, during acute exacerbations and particularly in disease progression [
1,
2]. Despite significant advances in diagnostic immunology and radiology, and a growing global awareness of bronchiectasis as a significant twenty-first century clinical problem, the underlying cause of bronchiectasis in a given patient is not always clear. Approximately 40% of cases remain idiopathic [
3], after the most common causes (immunodeficiencies, cystic fibrosis (CF), primary ciliary dysfunction (PCD), allergic bronchopulmonary aspergillosis (ABPA), connective tissue disorders, chronic obstructive pulmonary disease (COPD)-related, or asthma-related) have been excluded [
4,
5].
Respiratory infections in early childhood are an important cause of airway damage with the potential to initiate the vicious cycle of epithelial damage, airway dilatation, mucostasis, and bacterial colonisation [
6]. Prior to widespread vaccination in the mid twentieth century, measles and pertussis played a major role in post-infectious damage leading to bronchiectasis [
7]. The incidence and mortality of pneumonia associated with influenza and pneumococcal infection has also been reduced in both paediatric [
8‐
10] and adult populations with access to vaccination programs [
11,
12]. Pneumonia in childhood caused by common respiratory viruses has been associated with significant early airway damage and these viruses are emerging as major factors in the subsequent development of bronchiectasis [
4,
13]. While research has focused on defining the aetiology of bronchiectasis due to its implications in individualised treatment and management of the disease, little work has been done to define the role of respiratory viruses in stable and acute bronchiectasis.
As there is considerable phenotypic overlap between bronchiectasis, CF and COPD, the basic understanding gained from investigating the role of viruses in exacerbations and asymptomatic viral detection during stable phases in these diseases may guide our knowledge regarding bronchiectasis.
The association between viral infection and bacterial superinfection is well described in the literature, and more recently, with changes in the microbiome. In COPD and CF, respiratory viruses precipate exacerbations, which in turn, are associated with accelerated disease progression [
14]. Mallia et al. [
15] demonstrated that experimental rhinovirus infection in patients with COPD could induce symptoms associated with exacerbations, and induce changes in the microbiota. These findings in COPD have been further confirmed by a serial analysis of the lung microbiome following rhinovirus infection [
16]. In patients with CF, significantly higher levels of respiratory viruses were detected during exacerbations (46%) compared to stable phases (17%) [
17]. The detection of viruses during exacerbation has also been associated with an increase in colony counts of Pseudomonas aeruginosa, suggesting that viruses may also affect the stability of the microbiome in cystic fibrosis [
18]. In these diseases, increased viral presence was often observed during exacerbations which also lead to changes in the resident microbial communities. Bacterial colonisation is a common and key feature of the pathophysiology of bronchiectasis. Less is known about the role of viruses in stable state bronchiectasis, or the effect of viruses on the equilibrium between symbiotic and pathogenic bacterial species.
Therefore, this pilot study aimed to determine the incidence of respiratory virus testing ordered by physicians within a cohort of bronchiectasis patients with acute exacerbations at a teaching hospital and separately, to determine the incidence of viral detection within a group of patients with stable bronchiectasis to establish baseline viral prevalence. The incidence of symptomatic viral infections and rates of exacerbations in this cohort was also evaluated.
Discussion
Our small retrospective audit of admissions for exacerbation of bronchiectasis revealed how infrequently viral PCR testing was requested in a large teaching hospital with ready access to on site rapid respiratory viral PCR. Reflecting the current state of the literature, bacterial and fungal species were more frequently assumed to be the etiological agents and therefore, tested for in the majority of patients presenting with an exacerbation. Viral PCR testing was only requested in 28% of the bronchiectasis exacerbations included in the audit, compared with 88% of admissions where bacterial and fungal culture were requested.
However, despite the greater frequency of request for bacterial and fungal culture, viruses were still detected in 39% of the samples when viral PCR was requested, compared with bacterial or fungal pathogen detection in 30% of samples sent for testing. It is important that sampling rates increase, and prospective, longitudinal studies of both bacterial and viral pathogens in stable and exacerbating bronchiectasis are undertaken, if we are to understand with more precision, the role of viruses in exacerbations and their seasonality.
Due to the low rate of viral testing in acute exacerbations of bronchiectasis at our centre, we designed a study to determine the incidence of respiratory virus detection during stable periods and whether this was associated with an increased risk of exacerbation or developing a symptomatic viral infection. Studying stable patients with bronchiectasis provides information regarding the background level of viruses to inform future analysis of results obtained during acute exacerbations. Our pilot study demonstrated that respiratory viruses are commonly detected in respiratory secretions and the exhaled breath of patients with stable bronchiectasis. They are frequently detected during asymptomatic periods, and multiple viruses are often present concurrently.
In this study, there was a 92% detection rate in the winter cohort, and a 33% detection rate in the summer cohort. Other studies have detection rates of around 20% in stable bronchiectasis rising to around 40–50% in exacerbations in non-CF bronchiectasis in adults [
27,
28]. One potential reason for obtaining such high virus detection by PCR is contamination within the PCR reaction. We are confident that high viral detection rates in the winter cohort this is not caused by poor PCR technique or experimental contamination as out negative controls were always negative. Furthermore, whilst the samples were collected during different periods of the year, the PCRs were carried out simultaneously. However, we used a highly sensitive PCR which can detect as few as 5 virions. In our study, even low CT values were classified as viral positive whereas in other studies these might be classified as negative. Whist not a part of this study, we have compared our research lab virus PCR results to virus positivity by PCR obtained from a diagnostic lab. We found almost 100% agreement for all viruses, apart from rhinovirus, where we found our PCR was more sensitive (twice the detection frequency). We think that the most plausible explanation for the high sample detection in our winter cohort happened to be sampled during a year that was recognised to have a heavy burden of influenza infections. Other possible reasons might be the increased severity of bronchiectasis based on FEV
1 values in our cohort, and also, the high incidence of PCD as our clinic is a state-wide referral centre for PCD. However, it is unusual to have found such high rates of multiple virus detection, and further studies are needed in PCD to confirm these findings. There is currently little literature regarding the detection and persistence of respiratory viruses in the respiratory tract of individuals with PCD.
Respiratory viruses were more common during winter season, compared with the summer season. This study confirms previously reported seasonality of respiratory viruses [
29] for RSV, however rhinovirus has been shown to occur all year round in respiratory specimens which was not observed in this cross-sectional study of bronchiectasis patients. Influenza has also demonstrated peak detection during the winter months in temperate zones, and year-round distribution in tropical areas [
30]. In this study, we observed a heavy burden of influenza during the winter season, however influenza A virus was still detected in multiple asymptomatic individuals during the summer months.
Detection of respiratory viruses in the exhaled breath and sputum samples of this bronchiectasis cohort, was not significantly associated with disease severity or risk of exacerbation within the 2 month follow up period. In the one patient who was admitted to hospital with a bronchiectasis exacerbation within 2 weeks of their clinic visit, influenza A was present within both the exhaled breath and sputum sample. However, this was the only case where an exacerbation was associated with virus detection in our study. The short duration of this follow up time may not be adequate, however, to make a clear determination of exacerbation risk in this cohort. A longitudinal study design with regular viral sampling during periods of both stable disease and exacerbation, and more in depth analysis of patient outcomes may be needed to elucidate this risk.
No association was observed between viral detection and treatment with ICS/LABA or SABA alone. In the summer cohort, viruses were more commonly detected in patients with more severe disease as indicated by spirometry, with 80% patients who had influenza A detection demonstrating an FEV
1 below 30% predicted based on the GLI-2012 reference set [
31]. In the winter cohort, viral detection had no significant association with spirometry values.
Real time PCR allowed quantification of viral load, with higher viral load detection in the sputum sample predicting detection in the exhaled breath sample collected using the spirometry filters. Huang et al. [
32] showed that presence of influenza virus within the respiratory tract is necessary but not sufficient to cause a symptomatic influenza infection. Host immune responses play an important role, and activation of multiple simultaneous pattern recognition receptors to cause antiviral and inflammatory responses are associated with symptomatic infection. Individuals who retain tight control over these responses usually remain asymptomatic, and may explain why asymptomatic infection was so prevalent in our cohort. These patients with bronchiectasis all have chronic bacterial lung colonisation, which may play a role in downregulating immune responses [
33].
A surprising finding was that of influenza A detection only during the summer months. Traditionally, influenza A activity peaks during the winter months and viruses such as rhinovirus are more commonly seen in summer and early autumn. The Australian influenza surveillance network showed that there was a higher than normal level of influenza A detected during January to March of 2017, the sampling period of our summer cohort. Likely due to the fact that this group of bronchiectasis patients have an underlying respiratory disease, and impaired muco-ciliary clearance, it is possible that these individuals were more susceptible to acquiring these circulating viruses.
A large proportion of those recruited during the winter months had PCD as the underlying cause of bronchiectasis, as this study was undertaken at a tertiary referral centre for PCD. Ciliary dysmotility impairs mucociliary clearance and it seems plausible that this might result in persistence of viral nucleic acids within sputum, even if the virus is not actively replicating. Whilst the number of subjects in this pilot is small, it raises the possibility that differences in underlying pathophysiology of bronchiectasis extend to heterogeneity in the pathogenesis of viruses.
Since the introduction of culture-independent techniques, a substantial increase in bacterial detection has been observed [
34]. Molecular methods that identify bacterial species based on nucleic acid presence has greatly improved diagnostic accuracy [
35,
36], and has allowed discovery of a whole range of bacterial species that are present within the lower respiratory tract. The introduction of these molecular based methods such as PCR, have also allowed the detection of respiratory viral species to become faster and easier [
37]. This greatly increased the rate of respiratory infections that were found to be attributable to viruses, as this is a much more sensitive and specific tool. This was an important step in realising the high frequency of respiratory viral infections, and thus their importance in clinical disease. It also allowed a more guided approach to treatment, with a decrease in the use of antibacterial agents in some cases. Characterising the role of viruses in both stable bronchiectasis and during exacerbations may allow a greater understanding of disease pathogenesis.